In partnership with China Investment Corporation (CIC) and BNP Paribas, Eurazeo’s China head tells FinanceAsia how France's largest private equity company plans to spend up to Eur1.5 billion to break into the world’s second largest economy.
Alibaba’s successful HK listing, combined with mounting pressure from PE investors, is forcing Chinese companies to consider listing in 2020 despite the woeful stock market performance of many who floated in 2019.
As global investment into healthcare dips, some pre-IPO investors hold high hopes one Chinese pharma company can take on AstraZeneca and win big in the China respiratory drug market.
The $70 million Series D funding for CarDekho, is just the most recent example of Chinese funds using their expertise at home to make similar investment calls overseas.
Biotech investment is the new gold rush in China. But firms still struggle to find steady investment from private equity players and industry heavyweights.
While car sales continue to decline in China, Sequoia Capital China and Source Code Capital are betting on an increasing need for auto parts with CassTime.
Chinese investors have been flying to India over the past few months to check out VC and PE investment opportunities. Can China follow in the footsteps of the Americans and the Japanese?